Comparative Pharmacology
Head-to-head clinical analysis: ENLON versus MYTELASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENLON versus MYTELASE.
ENLON vs MYTELASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, inhibiting neuromuscular transmission.
Mytelase (ambenonium chloride) is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at cholinergic synapses by inhibiting its hydrolysis. This enhances neuromuscular transmission and improves muscle strength.
Intravenous: 0.1 mg/kg followed by 1-2 mg/min infusion for reversal of neuromuscular blockade; adjust based on twitch response.
Oral: 5–25 mg three times daily; maximum 100 mg/day. IV: 2–5 mg every 2–4 hours as needed for myasthenic crisis.
None Documented
None Documented
Terminal elimination half-life of 1.5-2.5 hours; prolonged in renal impairment and elderly patients
3-4 hours (short; requires frequent dosing every 3-4 hours for myasthenia gravis management).
Primarily renal excretion of unchanged drug (85-95%), with minor fecal elimination (<5%)
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal excretion (<5%).
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor